Join us for our Annual ALS Research Symposium!
November 4th & 5th 2020 for the ALS research and science industry! Via Zoom. Registration is free but required.
ALS ONE’s annual ALS ONE Research Symposium, hosted by Drs. Robert Brown, James Berry, Merit Cudkowicz, and Steve Perrin of ALS ONE, brings together researchers and scientists who are working on therapeutic options, and ultimately a cure, for Amyotrophic Lateral Sclerosis (ALS). This year’s topics are comprised of some of the most exciting updates on new and important disease topics in ALS, including:
- From Sporadic ALS (SALS) to Familial ALS (FALS): New biology and therapeutic opportunities.
- New insights into axonal trafficking and MN’s.
- HEALEY ALS Platform Trial updates roundtable discussion.
We are delighted and honored to feature the following Keynote Speakers:
- Merit Cudkowicz, MD, MsC
- Kevin Eggan, PhD
- Aaron Gitler, PhD
- Erika Holzbaur, PhD
- Clotilde Lagier-Tourenne, MD, PhD
- Nicholas John Maragakis, M.D.
- Dorothy (Dori) Schafer, PhD
- Jeremy Shefner, MD, PhD
- Michael Ward, MD, PhD
Our two-day conference, focused on the sharing of knowledge on ALS biology, clinical trial design and therapeutics, will include updates on current and planned clinical trials, new insights into designs and outcome measures, and a cross-pollination of ideas on ALS target and treatments. A panel discussion on the HEALEY ALS Platform trial will also be held to answer questions from Industry partners.
Attendance is free but prior registration is required. We hope to “see” you there!
In the past, ALS research has been fractured and duplicative with researchers working in silos—that environment creates a breeding ground for redundancy and inefficiency
The ALS ONE partnership unites leading ALS experts from a wide array of leading institutions as one team working toward a common goal. These stakeholders regularly communicate, share data, discuss findings, and establish best practices. This partnership improves coordination among research, care, and treatment teams, ultimately reducing the duplication of efforts.
The unprecedented linking of minds and resources from Massachusetts General Hospital (MGH), University of Massachusetts Medical Center, ALS Therapy Development Institute (ALS TDI), and Compassionate Care ALS (CCALS) is unique for its leadership in efficiency, dedication to innovative research, and commitment to increasing access to care and treatment.
From The Healey ALS Platform Trial at MGH, the very first ever of it’s kind, ALS TDI’s AT-1501 (Anti-CD40-Ligand Antibody) trial, to the anti-sense oligonucleotide (ASO) trial to target the C9orf72 gene under the direction of Dr. Brown at UMass Memorial; among many others, you can feel confident that your donations are impacting cutting edge and promising collaborative research. Meet our team
Patients with ALS can’t afford to wait—the typical life expectancy upon diagnosis is 2-5 years
The partnerships forged by ALS ONE bring efficiency and improved coordination to the fields of ALS research and care. The ALS ONE patient network creates a direct pipeline from therapy discovery, to immediate implementation, and to patient services.
Supporting Clinical Trials
Researchers are faced with myriad challenges that make it difficult to secure necessary data and benchmarks while they work to move novel therapies forward
ALS ONE is investing in technologies that help ease the research process and better enable patients to meet with clinicians and attend clinical trials in a safe environment.